ONCAlert | 2018 ASCO Annual Meeting

Biosimilars MORE >>

Progression-free survival was found to be almost identical at 48 weeks with MYL-1401O in combination with a taxane as initial therapy followed by MYL-1401O monotherapy as maintenance versus trastuzumab in patients with HER2-positive metastatic breast cancer, according to phase III findings of the HERITAGE trial. Results of the trial were presented at the 2018 ASCO Annual Meeting.

Latest JournalAll Journals >>

Copyright © TargetedOnc 2018 Intellisphere, LLC. All Rights Reserved.